| Fixed dose drug combinations–are they pharmacoeconomically sound? Findings and implications especially for lower-and middle-income countries B Godman, H McCabe, T D Leong, D Mueller, AP Martin, I Hoxha, ... Expert review of pharmacoeconomics & outcomes research 20 (1), 1-26, 2020 | 97 | 2020 |
| Characteristics of clinical trials in rare vs. common diseases: A register-based Latvian study K Logviss, D Krievins, S Purvina PLoS One 13 (4), e0194494, 2018 | 40 | 2018 |
| Impact of orphan drugs on Latvian budget K Logviss, D Krievins, S Purvina Orphanet journal of rare diseases 11, 1-13, 2016 | 31 | 2016 |
| Rare diseases and orphan drugs: Latvian story K Logviss, D Krievins, S Purvina Orphanet Journal of Rare Diseases 9, 1-13, 2014 | 31 | 2014 |
| Oral delivery of cannabidiol: Revealing the formulation and absorption challenges A Sitovs, K Logviss, L Lauberte, V Mohylyuk Journal of Drug Delivery Science and Technology, 105316, 2023 | 7 | 2023 |
| Adherence level to arterial hypertension treatment: A cross-sectional patient survey and retrospective analysis of the nhs prescription database A Gavrilova, D Bandere, K Logviss, D Šmits, I Urtāne Healthcare 9 (8), 1085, 2021 | 7 | 2021 |
| Chemical Profiling and Antioxidant Activity of Tanacetum vulgare L. Wild-Growing in Latvia R Šukele, L Lauberte, L Kovalcuka, K Logviss, A Bārzdiņa, A Brangule, ... Plants 12 (10), 1968, 2023 | 6 | 2023 |
| A comparative analysis of the proanthocyanidins from fruit and non-fruit trees and shrubs of Northern Europe: Chemical characteristics and biological activity A Andersone, S Janceva, L Lauberte, I Skadins, V Nikolajeva, K Logviss, ... Sustainable Chemistry and Pharmacy 36, 101266, 2023 | 3 | 2023 |
| Quantification of Soluplus® and copovidone polymers in dissolution media: Critical systematic review ZM Horváth, L Lauberte, K Logviss, D Bandere, V Mohylyuk Journal of Drug Delivery Science and Technology, 104998, 2023 | 3 | 2023 |
| Evaluation of Oleogels Stabilized by Particles of Birch Outer Bark Extract through a Novel Approach S Vitolina, R Berzins, J Rizhikovs, D Godina, ZM Horváth, K Logviss, ... Gels 9 (11), 911, 2023 | 2 | 2023 |
| Trends in individual reimbursement of orphan drugs in Latvia in 2008–2011 K Logviss, D Krievins, S Purvina SHS Web of Conferences 10, 00021, 2014 | 2 | 2014 |
| Flavonoids in the Spotlight: Bridging the Gap between Physicochemical Properties and Formulation Strategies M Berga, K Logviss, L Lauberte, A Paulausks, V Mohylyuk Pharmaceuticals 16 (10), 1407, 2023 | 1 | 2023 |
| Orphan Drugs in Surgery K Logviss, D Krievins, S Purvina Acta Chirurgica Latviensis 13 (1), 57-62, 2013 | 1 | 2013 |
| Līdzestības līmenis arteriālās hipertensijas ārstēšanā: šķērsgriezuma pacientu aptauja un NVD recepšu datubāzes retrospektīva analīze A Gavrilova, D Bandere, K Logviss, D Šmits, I Urtāne | | 2021 |
| Adherence level valuation depending on the duration of therapy among patients with arterial hypertension A Gavrilova, D Bandere, K Logviss, D Šmits, I Urtāne RSU Research week 2021: Knowledge for Use in Practice, 2021 | | 2021 |
| Pharmacoepidemiologic and Pharmacoeconomic Latvian Study of Rare Diseases and Orphan Drugs. Summary of the Doctoral Thesis K Logviss Rīga Stradiņš University, 2018 | | 2018 |
| Latvijā sastopamo reto slimību un to ārstēšanai izmantojamo orfānmedikamentu farmakoepidemioloģiski ekonomisks pētījums. Promocijas darba kopsavilkums K Logviss Rīgas Stradiņa universitāte, 2018 | | 2018 |
